Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134860 | 1.00 | ADRB3 (0.60) | ADRB3ADRB1 | |
| SCHEMBL6133718 | 0.94 | ADRB3 (0.53) | ADRB3ADRB1 | |
| SCHEMBL6133714 | 0.94 | ADRB3 (0.53) | ADRB3ADRB1 | |
| SCHEMBL6134383 | 0.93 | ADRB3 (0.52) | ADRB3ADRB1 | |
| SCHEMBL6134388 | 0.93 | ADRB3 (0.52) | ADRB3ADRB1 | |
| SCHEMBL6135094 | 0.92 | ADRB3 (0.53) | ADRB3ADRB1 | |
| SCHEMBL6135090 | 0.92 | ADRB3 (0.53) | ADRB3ADRB1 | |
| SCHEMBL6134499 | 0.91 | ADRB3 (0.61) | ADRB3ADRB1 | |
| SCHEMBL6134502 | 0.91 | ADRB3 (0.61) | ADRB3ADRB1 | |
| SCHEMBL6133649 | 0.90 | ADRB3 (0.64) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090669-A1 | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | ASTELLAS PHARMA INC. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1483236-A1 | AMINOALCOHOL DERIVATIVES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076397-A1 | AMINOALCOHOL DERIVATIVES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090669-A1 | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB3 3/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.